SLC5A2 and type 2 diabetes mellitus: Among these, sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors have shown promising efficacy and safety profiles in the management of T2DM.[11–14] Dapagliflozin, a representative SGLT2 inhibitor, lowers blood glucose by inhibiting SGLT2 in the proximal renal tubules, thereby reducing glucose reabsorption and increasing urinary glucose excretion.